This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the efficacy and safety of coformulated
El propósito de este estudio es comparar pembrolizumab (MK-3475) en combinación con sacituzumab govitecan con pembrolizumab solo con respecto a la supervivencia sin progresión (PFS) y la supervivencia global (OS) según los criterios de evaluación de respuesta en tumores sólidos versión 1.1 (RECIST 1.1) según lo evaluado por la revisión central independiente a ciego (BICR) … Continued
The purpose of this study is to evaluate the efficacy and safety of nemtabrutinib compared to investigator’s choice of fludarabine plus cyclophosphamide plus rituximab (FCR) or bendamustine plus rituximab (BR) in
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with pembrolizumab, with or without chemotherapy, for the treatment of participants
The purpose of this study is to assess the safety and efficacy of pembrolizumab plus standard of care (SOC) chemotherapy (etoposide/platinum [EP]) in participants with newly diagnosed extensive stage small cell
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts
